US2009060843A1PendingUtilityA1
Non-Invasive In Vivo Imaging and Methods for Treating Type I Diabetes
Est. expiryAug 31, 2027(~1.1 yrs left)· nominal 20-yr term from priority
A61P 7/12A61P 31/00A61P 5/50A61P 3/10C12N 2830/008A61K 49/0008A61K 35/39A01K 2267/0325A01K 2217/05C12N 5/0676A01K 67/0271A01K 2227/105
62
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides novel drug discovery platforms and methods for treating type I diabetes.
Claims
exact text as granted — not AI-modified1 . A method for drug development comprising
(a) engrafting target cells into the eye of a test animal, wherein one or more cellular component of therapeutic interest in the transplanted target cells are fluorescently labeled; (b) contacting the target cells with one or more test compounds; and (c) performing non-invasive fluorescent imaging on the eye of the test animal,
wherein the fluorescent imaging is used to detect test compound-induced changes in one or more of activity, location, and amount of the fluorescently labeled cellular components of therapeutic interest in the engrafted target cells, wherein the changes identify those test compounds that may provide a therapeutic benefit to the target cells.
2 . The method of claim 1 , wherein the target cells are derived from tissue selected from the group consisting of endocrine, fat, muscle, brain, liver, heart, kidney, and lung.
3 . The method of claim 1 wherein the target cells are transplanted into the anterior chamber of the eye of the test animal.
4 . The method of claim 1 , wherein the one or more test compounds are applied topically onto the eye of the test animal.
5 . The method of claim 1 wherein the one or more test compounds are injected into the anterior chamber of the eye of the test animal.
6 . The method of claim 1 wherein the fluorescent imaging comprises laser-scanning microscopy.
7 . The method of claim 1 wherein the fluorescent imaging is used to detect test compound-induced changes in one or more of activity, location, and amount of the fluorescently labeled cellular components of therapeutic interest in the engrafted target cells at multiple time points.
8 . The method of claim 1 wherein the target cells comprise pancreatic beta cells.
9 . A method for treating a subject with type I diabetes, comprising transplanting into the eye of a subject with type I diabetes an amount effective of an insulin-producing cell to promote insulin production in the subject.Join the waitlist — get patent alerts
Track US2009060843A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.